Edwards Lifesciences sells Critical Care unit to BD for $4.2B cash, ends spin-off

Edwards Lifesciences Corp

All-cash sale of Critical Care product group to BD (NYSE: BDX) valued at $4.2 billion.
Edwards will no longer pursue the previously announced spin-off of Critical Care.
Transaction expected to close by end of 2024; impact to 2024 adjusted EPS immaterial.
Critical Care will remain in Irvine, CA, led by current corporate VP Katie Szyman.
After-tax cash proceeds to fund strategic structural heart innovation investments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.